Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 194-209 http://medscipublisher.com/index.php/cge 196 biomarkers elevated in the blood of cancer patients, such as carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9), can indicate the presence of malignancies (Kneuertz et al., 2015). The integration of non-invasive biomarkers into clinical practice has the potential to revolutionize colon cancer screening and diagnosis, making it more accessible and effective (Figure 1). Figure 1 Non-Invasive Biomarkers in CC 3 Types of Non-Invasive Biomarkers 3.1 Circulating tumor DNA (ctDNA) Circulating tumor DNA (ctDNA) consists of fragmented DNA molecules shed from tumor cells into the bloodstream. These fragments contain genetic and epigenetic alterations specific to the cancerous cells, making them valuable for non-invasive cancer detection and monitoring. In colon cancer, ctDNA can be detected in the plasma and provides a comprehensive overview of the genetic landscape of tumors, including mutations in genes such as APC, KRAS, and TP53. The presence and quantity of ctDNA correlate with tumor burden, disease stage, and response to treatment, making it a useful biomarker for early detection, prognosis, and monitoring of therapeutic efficacy. Studies have demonstrated the utility of ctDNA in identifying minimal residual disease and predicting recurrence, which is particularly important for post-surgical monitoring of colon cancer patients. For instance, Bhardwaj et al. (2020) showed that a combination of multiple protein markers, including ctDNA, could significantly improve early detection of colorectal cancer. Moreover, Wilhelmsen et al. (2017) emphasized the importance of integrating ctDNA analysis with other blood-based biomarkers to enhance diagnostic accuracy and provide a more detailed understanding of tumor dynamics. The non-invasive nature of ctDNA testing allows for frequent monitoring without the need for invasive procedures, thereby improving patient compliance and enabling timely adjustments in treatment strategies. As research progresses, ctDNA analysis is expected to play a crucial role in personalized medicine, providing tailored treatment plans based on the genetic profile of individual tumors. 3.2 Circulating tumor Cells (CTCs) Circulating tumor cells (CTCs) are cancer cells that detach from the primary tumor and circulate in the bloodstream. These cells are pivotal in the metastatic process and their detection can provide critical insights into the progression and spread of colon cancer. The enumeration and characterization of CTCs offer a non-invasive
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==